Summary
It’s a brave new world for biotech.
Shares of Intellia Therapeutics — a company that has the potential to “edit” defective genes — soared 23 percent in its trading debut on Friday.
The Cambridge, Mass.-based firm, which sold 6 million shares at $18 apiece, closed at $22.10.
…
“What’s amazing about Crispr is that it is cheap and easy,” said Hank Greely, the director for Stanford’s Law and Biosciences Center.
Read More